Serotonergic impairment and memory deficits in adolescent rats after binge exposure of methylone

Journal of Psychopharmacology

Volumn 28, Issue 11, 2014, Pages 1053-1063

  López Arnau, Raúl ^a   Martínez Clemente, José ^a   Pubill, David ^a   Escubedo, Elena ^a   Camarasa, Jorge ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

frontal cortex; hippocampus; Methylone; neurotoxicity; rat; striatum

Indexed keywords

DOPAMINE; METHYLONE; SEROTONIN; SEROTONIN 2A RECEPTOR; TRYPTOPHAN HYDROXYLASE 2; TYROSINE 3 MONOOXYGENASE; DESIGNER DRUG; DOPAMINE TRANSPORTER; METHAMPHETAMINE; SEROTONIN TRANSPORTER; TPH2 PROTEIN, RAT; TRYPTOPHAN HYDROXYLASE;

ADOLESCENT; AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; ASTROCYTOSIS; BODY WEIGHT; CELL ACTIVATION; CONTROLLED STUDY; CORE TEMPERATURE; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; ENVIRONMENTAL TEMPERATURE; FRONTAL CORTEX; HIPPOCAMPUS; HYPERTHERMIA; IN VIVO STUDY; LETHALITY; MALE; MICROGLIA; MORRIS WATER MAZE TEST; NEUROTOXICITY; NONHUMAN; PROTEIN EXPRESSION; RAT; REFERENCE MEMORY; SEROTONIN UPTAKE; SEROTONINERGIC SYSTEM; SPATIAL LEARNING; SPATIAL MEMORY; ANALOGS AND DERIVATIVES; ANIMAL; BIOSYNTHESIS; CHEMICALLY INDUCED; DRUG EFFECTS; FRONTAL LOBE; GLIOSIS; MAZE TEST; MEMORY DISORDER; METABOLISM; PATHOLOGY; PSYCHOLOGY; RADIOASSAY; SEROTONINERGIC NERVE CELL; TOXICITY AND INTOXICATION;

ANIMALS; CORPUS STRIATUM; DESIGNER DRUGS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FRONTAL LOBE; GLIOSIS; HIPPOCAMPUS; MALE; MAZE LEARNING; MEMORY DISORDERS; METHAMPHETAMINE; NEUROTOXICITY SYNDROMES; RADIOLIGAND ASSAY; RATS; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONERGIC NEURONS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TRYPTOPHAN HYDROXYLASE; TYROSINE 3-MONOOXYGENASE;

EID: 84910045789     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881114548439     Document Type: Article

References (53)

1. Baumann MH, Ayestas MA, Partilla JS, et al. The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology. 2012 ; 37: 1192-1203
2. Baumann MH, Partilla JS, Lehner KR. Psychoactive 'bath salts': Not so soothing. Eur J Pharmacol. 2013 ; 698: 1-5
3. Biezonski DK, Meyer JS. The nature of 3,4-methylenedioxy-methamphetamine (MDMA)-induced serotonergic dysfunction: Evidence for and against the neurodegeneration hypothesis. Curr Neuropharmacol. 2011 ; 9: 84-90
4. Blum K, Foster Olive M, Wang KKW, et al. Hypothesizing that designer drugs containing cathinones ('bath salts') have profound neuro-inflammatory effects and dangerous neurotoxic response following human consumption. Med Hypotheses. 2013 ; 81: 450-455
5. Bossong MG, Van Dijk JP, Niesink RJM. Methylone and mCPP, two new drugs of abuse?. Addict Biol. 2005 ; 10: 321-323
6. Carbone PN, Carbone DL, Carstairs SD, et al. Sudden cardiac death associated with methylone use. Am J Forensic Med Pathol. 2013 ; 34: 26-28
7. Carneiro AMD, Blakely RD. Serotonin-, protein kinase C-, and Hic-5-associated redistribution of the platelet serotonin transporter. J Biol Chem. 2006 ; 281: 24769-24780
8. Cawrse BM, Levine B, Jufer RA, et al. Distribution of methylone in four postmortem cases. J Anal Toxicol. 2012 ; 36: 434-439
9. Cuyas E, Robledo P, Pizarro N, et al. 3,4-methylenedioxymethamphetamine induces gene expression changes in rats related to serotonergic and dopaminergic systems, but not to neurotoxicity. Neurotox Res. 2014 ; 25: 161-169
10. Davies S, Wood DM, Smith G, et al. Purchasing 'legal highs' on the Internet - is there consistency in what you get?. Q J Med. 2010 ; 103: 489-493
11. den Hollander B, Rozov S, Linden A-M, et al. Long-term cognitive and neurochemical effects of 'bath salt' designer drugs methylone and mephedrone. Pharmacol Biochem Behav. 2013 ; 103: 501-509
12. D'Hooge R, De Deyn PP. Applications of the Morris water maze in the study of learning and memory. Brain Res Rev. 2001 ; 36: 60-90
13. Schedules of controlled substances: Placement of methylone into Schedule I. Fed Regist. 2013 ; 78: 21818-21825
14. Escubedo E, Chipana C, Pérez-Sánchez M, et al. Methyllycaconitine prevents methamphetamine-induced effects in mouse striatum: Involvement of alpha7 nicotinic receptors. J Pharmacol Exp Ther. 2005 ; 315: 658-667
15. Eshleman AJ, Wolfrum KM, Hatfield MG, et al. Substituted methcathinones differ in transporter and receptor interactions. Biochem Pharmacol. 2013 ; 85: 1803-1815
16. Finnegan KT, Ricaurte GA, Ritchie LD, et al. Orally administered MDMA causes a long-term depletion of serotonin in rat brain. Brain Res. 1988 ; 447: 141-144
17. Fleckenstein AE, Volz TJ, Riddle EL, et al. New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol. 2007 ; 47: 681-698
18. Hadlock GC, Webb KM, McFadden LM, et al. 4-methylmethcathinone (mephedrone): Neuropharmacological effects of a designer stimulant of abuse. J Pharmacol Exp Ther. 2011 ; 339: 530-536
19. Halpin LE, Collins SA, Yamamoto BK. Neurotoxicity of methamphetamine and 3,4-methylenedioxymethamphetamine. Life Sci. 2014 ; 97: 37-44
20. Herndon JM, Cholanians AB, Lizarraga LE, et al. Catechol-O-methyltransferase and 3,4-({+/-})-methylenedioxy-methamphetamine toxicity. Toxicol Sci. 2014 ; 138: 130-138
21. Hewitt KE, Green AR. Chlormethiazole, dizocilpine and haloperidol prevent the degeneration of serotonergic nerve terminals induced by administration of MDMA ('Ecstasy') to rats. Neuropharmacology. 1994 ; 33: 1589-1595
22. Ho YJ, Pawlak CR, Guo L, et al. Acute and long-term consequences of single MDMA administration in relation to individual anxiety levels in the rat. Behav Brain Res. 2004 ; 149: 135-144
23. Itzhak Y, Ali SF, Achat CN, et al. Relevance of MDMA ("ecstasy")-induced neurotoxicity to long lasting psychomotor stimulation in mice. Psychopharmacology. 2003 ; 166: 241-248
24. Kehr J, Ichinose F, Yoshitake S, et al. Mephedrone, compared with MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and 5-HT levels in nucleus accumbens of awake rats. Br J Pharmacol. 2011 ; 164: 1949-1958
25. Kirilly E, Molnar E, Balogh B, et al. Decrease in REM latency and changes in sleep quality parallel serotonergic damage and recovery after MDMA: A longitudinal study over 180 days. Int J Neuropsychopharmacol. 2008 ; 11: 795-809
26. Logan BJ, Laverty R, Sanderson WD, et al. Differences between rats and mice in MDMA (methylenedioxymethylamphetamine) neurotoxicity. Eur J Pharmacol. 1988 ; 152: 227-234
27. López-Arnau R, Martínez-Clemente J, Abad S, et al. Repeated doses of methylone, a new drug of abuse, induce changes in serotonin and dopamine systems in the mouse. Psychopharmacology. 2014 ; 231: 3119-3129
28. López-Arnau R, Martínez-Clemente J, Carbó M, et al. An integrated pharmacokinetic and pharmacodynamic study of a new drug of abuse, methylone, a synthetic cathinone sold as 'bath salts'. Prog Neuropsychopharmacol Biol Psychiatr. 2013 ; 45: 64-72
29. López-Arnau R, Martínez-Clemente J, Pubill D, et al. Comparative neuropharmacology of three psychostimulant cathinone derivatives: Butylone, mephedrone and methylone. Br J Pharmacol. 2012 ; 167: 407-420
30. McCardle K, Luebbers S, Carter JD, et al. Chronic MDMA (ecstasy) use, cognition and mood. Psychopharmacology. 2004 ; 173: 434-439
31. McElrath K, O'Neill C. Experiences with mephedrone pre- and post-legislative controls: Perceptions of safety and sources of supply. Int J Drug Policy. 2011 ; 22: 120-127
32. McGregor IS, Gurtman CG, Morley KC, et al. Increased anxiety and 'depressive' symptoms months after MDMA ('ecstasy') in rats: Drug-induced hyperthermia does not predict long-term outcomes. Psychopharmacology. 2003 ; 168: 465-474
33. Martínez-Clemente J, Escubedo E, Pubill D, et al. Interaction of mephedrone with dopamine and serotonin targets in rats. Eur Neuropsychopharmacol. 2012 ; 22: 231-236
34. Marusich JA, Grant KR, Blough BE, et al. Effects of synthetic cathinones contained in 'bath salts' on motor behavior and a functional observational battery in mice. Neurotoxicology. 2012 ; 33: 1305-1313
35. Moon M, Do KS, Park J, et al. Memory impairment in methamphetamine dependent patients. Int J Neurosci. 2007 ; 117: 1-9
36. Motbey CP, Hunt GE, Bowen MT, et al. Mephedrone (4-methylmethcathinone, 'meow'): Acute behavioural effects and distribution of Fos expression in adolescent rats. Addict Biol. 2012 ; 17: 409-422
37. Mueller PD, Korey WS. Death by 'ecstasy': The serotonin syndrome?. Ann Emerg Med. 1998 ; 32: 377-380
38. Myhrer T. Neurotransmitter systems involved in learning and memory in the rat: A meta-analysis based on studies of four behavioral tasks. Brain Res Rev. 2003 ; 41: 268-287
39. Parrott AC, Sisk E, Turner JJ. Psychobiological problems in heavy 'ecstasy' (MDMA) polydrug users. Drug Alcohol Depend. 2000 ; 60: 105-110
40. Pearson JM, Hargraves TL, Hair LS, et al. Three fatal intoxications due to methylone. J Anal Toxicol. 2012 ; 36: 444-451
41. Piper BJ, Meyer JS. Memory deficit and reduced anxiety in young adult rats given repeated intermittent MDMA treatment during the periadolescent period. Pharmacol Biochem Behav. 2004 ; 79: 723-731
42. Pubill D, Canudas AM, Pallàs M, et al. Different glial response to methamphetamine- and methylenedioxymethamphetamine-induced neurotoxicity. N-S Arch Pharmacol. 2003 ; 367: 490-499
43. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008 ; 22: 659-661
44. Reneman L, Booij J, Majoie CBLM, et al. Investigating the potential neurotoxicity of Ecstasy (MDMA): An imaging approach. Hum Psychopharmacol. 2001 ; 16: 579-588
45. Richter-Levin G, Segal M. Spatial performance is severely impaired in rats with combined reduction of serotonergic and cholinergic transmission. Brain Res. 1989 ; 477: 404-407
46. Sanchez V, O'Shea E, Saadat KS, et al. Effect of repeated ('binge') dosing of MDMA to rats housed at normal and high temperature on neurotoxic damage to cerebral 5-HT and dopamine neurones. J Psychopharmacol. 2004 ; 18: 412-416
47. Simmler LD, Buser TA, Donzelli M, et al. Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol. 2013 ; 168: 458-470
48. Slikker W, Ali SF, Scallet AC, et al. Neurochemical and neurohistological alterations in the rat and monkey produced by orally administered methylenedioxymethamphetamine (MDMA). Toxicol Appl Pharmacol. 1988 ; 94: 448-457
49. Sogawa C, Sogawa N, Ohyama K, et al. Methylone and monoamine transporters: Correlation with toxicity. Curr Neuropharmacol. 2011 ; 9: 58-62
50. Spiller HA, Ryan ML, Weston RG, et al. Clinical experience with and analytical confirmation of 'bath salts' and 'legal highs' (synthetic cathinones) in the United States. Clin Toxicol. 2011 ; 49: 499-505
51. Vardakou I, Pistos C, Spiliopoulou C. Drugs for youth via Internet and the example of mephedrone. Toxicol Lett. 2011 ; 201: 191-195
52. Volkow ND, Chang L, Wang GJ, et al. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neurosci. 2001 ; 23: 9414-9418
53. Vorhees CV, Williams MT. Morris water maze: Procedures for assessing spatial and related forms of learning and memory. Nat Protoc. 2006 ; 1: 848-858